Key MessageIn this nationwide study, management of patients with sarcoma and aggressive mesenchymal tumors within a network of reference centers endorsed by the National cancer institute was found associated with an improved adherence to international clinical practice guidelines, improvement quality of surgical management and reduced risk of relapse and death.

Introduction
============

Sarcomas are a heterogeneous group of rare connective tissue cancers, with variable clinical presentations, and an estimated incidence close to 6.2/100 000/year \[[@mdz124-B1]\]. In all clinical practice guidelines, it is recommended that the management of sarcoma patients should be carried out by a dedicated multidisciplinary team, including expert pathologists and surgeons, treating a large number of patients \[[@mdz124-B5]\]. Because of their rarity, sarcoma is often initially misrecognized, misdiagnosed, and as a consequence not treated according to clinical practice guidelines \[[@mdz124-B5]\]. Inadequate diagnostic procedure and treatment, e.g. enucleation of the tumor as initial surgery without initial imaging or biopsy, are observed in a large fraction of patients and often qualified as 'whoops' procedures \[[@mdz124-B10]\]. We recently reported that presentation to a specialized multidisciplinary tumor board (MDTB) was independently correlated to reduction in the risk of relapse in a nationwide study involving the NETSARC Network \[[@mdz124-B12]\]. Similar observations were reported by several other national initiatives \[[@mdz124-B13]\].

Optimal surgical removal of sarcoma, with *enbloc* macroscopic resection and histological clear margins is the mainstay of the curative treatment of localized soft tissue sarcoma (STS) \[[@mdz124-B5]\]. This quality of initial surgery is a major prognostic factor for recurrence-free survival and overall survival (OS) in all series \[[@mdz124-B16]\].

In most European (and actually worldwide) countries, including France, the treatment of patients with sarcoma can be carried out primary care oncology hospital or clinic, with no specific guidance on the nature of the required multidisciplinary team or on number of patients treated. Conversely in Scandinavian countries as well as in the UK the management of sarcoma patients must be carried out in dedicated reference centers \[[@mdz124-B9], [@mdz124-B22]\]. It is also recommended that patients with a suspected diagnosis of sarcoma should be referred at a sarcoma center before any treatment in international Clinical Practice Guidelines \[[@mdz124-B5]\].

The French National Cancer Institute (INCa) funded a clinical network for sarcoma (called NETSARC) in 2009, to improve the management and outcome of sarcoma patients. Twenty-six reference centers throughout the nation were identified. A Network for expert pathology diagnosis in sarcoma (RRePS) gathering 23 reference centers for pathology in charge of the second histological review for each suspected case was also created. A common database (netsarc.org) gathering all cases of sarcoma presented to MDTB was created and implemented, collected data on the diagnostic, therapeutic management, and the clinical outcome in terms of relapse and survival.

From 1 January 2010 to 1 May 2018, this database prospectively included a 47 023 patient population with 35 784 patients with sarcoma or tumor of intermediate malignancy. 11 239 (24%) patients in the database discussed in a NETSARC MDTB had a diagnosis which was not that of a sarcoma (benign tumor, e.g. lipoma, carcinoma, lymphoma, etc.).

The aim of the present study was to evaluate (i) the impact of predisposing conditions and patient history and (ii) the impact of surgery carried out in a NETSARC reference center on relapse and survival in the population of patients included in the NETSARC database.

Patients and methods
====================

The network
-----------

Each NETSARC center organizes an MDTB gathering sarcoma specialized pathologist(s), radiologist(s), surgeon(s), radiation oncologist(s), medical oncologist(s), and often molecular biologist(s), orthopedist(s), and pediatrician(s). All sarcoma or suspected sarcoma patient cases presented to the MDTB of all 26 centers were recorded in the database, by a dedicated team of Clinical research assistant, supervised by three coordinating centers (Centre Leon Bérard, Gustave Roussy, Institut Bergonié). Patient files may be presented before any diagnostic procedure, before initial biopsy, before primary surgery, after primary surgery, at relapse, and/or in case of a possible inclusion in a clinical trial. Patients and treatment data were prospectively included and regularly updated by the dedicated study coordinators. A monitoring of the centers activity is carried out by the three coordinating centers on a regular basis. The contribution of the different centers is presented in [supplementary Table S1](#sup1){ref-type="supplementary-material"} (available at *Annals of Oncology* online).

The NETSARC database
--------------------

The NETSARC database allows (i) to exhaustively describe the incident and prevalent population of sarcoma patients in France, by cross comparison of the pathological review database (rreps.org) and of the clinical database (netsarc.org), (ii) to monitor the diagnostic and initial treatment procedures, and (iii) to monitor patient outcome in particular survival and relapse. The database includes a limited set of data, on purpose, describing patients and tumor characteristics, surgery, relapse, and survival \[[@mdz124-B12]\]. The center which carried out the first resection is documented, as well as potential secondary surgery, and the final quality of resection after all surgical procedures. The surgical resection system (R) from the Union Internationale contre le Cancer was chosen to define the quality of surgery, including the margins of resection. This system defines the quality of resection (R) using the surgical and pathological report: R0 = macroscopically complete resection with an absence of tumor cells in the resection margins, R1 = same, but with tumor cells visible on resection margins, and R2 = macroscopic residual disease.

Of note, 11 239 (24%) out of the 47 023 patients in the database discussed in a NETSARC MDTB had a diagnosis which was not that of a sarcoma (benign tumor, e.g. lipoma, carcinoma, lymphoma, etc.). The case was presented for discussion after the pathology review for further discussion, or before the pathology review (which was then conducted afterward at the request of the MDTB). It is important to note that in NETSARC, patients with sarcoma or suspected sarcoma can enter the process of MDTB either through the pathology network, or directly by the physician, leading in both cases to a final MDTB review after central pathology confirmation. All data presented here were extracted from the NETSARC.org database accessible online.

Statistical analyses
--------------------

The categorical data were summarized by the frequencies and percentages, and the continuous covariates have been summarized with median, range, and numbers of observations. The statistical test used for comparison was a chi-square test (or a Fisher's exact test) for categorical covariates, without adjustment for multiple comparisons. The diagnostic date is the date of histological diagnosis (biopsy or first surgery). Survival is calculated from the date of diagnosis to the date of last follow-up or death. Local relapse free survival (LRFS) is computed from the diagnostic date to the date of the last follow-up or the date of the first local recurrence. Event-free survival (EFS) was computed from the date of diagnosis to the date of the last follow-up or the date of the first local relapse, metastasis progression or death, whichever comes first.

Survival curves were plotted using a Kaplan--Meier method. Survival was compared using the log-rank test. Univariate and multivariate analysis for LRFS, EFS, and OS included (i) classical prognostic factors for sarcoma \[age, gender, grade, size, site, metastasis at diagnosis, histotypes---in particular the most frequent histotypes leiomyosarcoma (LMS), LPS, undifferentiated pleomorphic sarcoma (UPS), gastrointestinal stromal tumor (GIST), etc.\] and (ii) also preexisting conditions which are collected routinely in the NETSARC database \[previous cancer, neurofibromatosis type 1 (NF1), p53, previous radiotherapy (RT)\] \[[@mdz124-B18]\]. It also included prognostic factors identified in univariate analysis, e.g. presentation to a NETSARC MDTB before versus after first treatment, primary and/or secondary surgery in a NETSARC center. Cox proportional hazards model was used for the multivariate analysis, introducing parameters significant (*P* \< 0.05) in univariate analysis. Factors included in the multivariate model were identified by a backward selection procedure which entails including all the covariates in the model and removing those, whose *P*-value is higher than 0.10, one at a time. At each step of the model, all included variables were tested and removed if they were no longer associated with the outcome considering a 5% type I error (*P*-value ≥0.05). All statistical tests were two-sided. All statistical analyses were carried out using SPSS (version 22.0).

Results
=======

Patient population
------------------

Between 1 January 2010 and 1 May 2018, 35 784 patients with sarcoma or mesenchymal tumors of intermediate malignancy were prospectively included in the NETSARC database. 29 467 (82.4%) patients were diagnosed from 1 January 2010 onward (designated as the incident population) and 6287 patients were diagnosed before, but presented to a NETSARC MDTB after 1 January 2010. The patient population studied here is that of all patients included in the database, of any age, with a histologically reviewed and confirmed soft tissue or visceral sarcoma, GIST, bone sarcomas, or tumor of intermediate malignancy in any anatomic site. Patient characteristics are presented in Table [1](#mdz124-T1){ref-type="table"}.

###### 

Description of the population of 35 784 patients with connective tissue tumors in Netsarc

  Characteristics                                       Total (*N* = 35 784)   Populations *N* (%) incident   Operated in NETSARC (*N* = 9954)   *P* [^a^](#tblfn1){ref-type="table-fn"}
  ----------------------------------------------------- ---------------------- ------------------------------ ---------------------------------- -----------------------------------------
  Gender                                                                                                                                         
   Male                                                 17 577 (49.1%)         14 661 (49.5%)                 4983 (50.1%)                       
   Female                                               18 207 (50.9%)         14 886 (50.5%)                 4971 (49.9%)                       0.19
  Age at first diagnosis                                                                                                                         
   Mean (min--max)                                      60.8 (0--106)          55.3 (0--106)                  53.8 (0--99)                       0.000
   \<18                                                 1622 (4.5%)            1359 (4.6%)                    522(5.2%)                          
   18--40                                               7019 (19.6%)           5682 (19.3%)                   2009 (20.2%)                       
   41--60                                               10 993 (30.7%)         8763 (29.7%)                   3056 (30.7%)                       
   61--80                                               12 599 (35.2%)         11 070 (37.5%)                 3711 (37.3%)                       
   \>80                                                 2736 (7.6%)            2622 (8.9%)                    656 (6.6%)                         
   Missing                                              815 (2.3%)             1 (0.0%)                       0                                  0.000
  Size of the tumor (mm)                                                                                                                         
   Available in *N* = 11 894 (33.2%)                                                                                                             
   Median (min--max)                                    91 (1--900)            89.6 (1--900)                  97.7 (1--600)                      0.000
  Primary site                                                                                                                                   
   Soft tissue                                          22 971 (64.2%)         19 288 (65.4%)                 6398 (64.3%)                       
   Visceral                                                                    5681 (19.3%)                   1404 (14.1%)                       
   Bone                                                 5447 (15.2%)           4528 (15.4%)                   2152 (21.6%)                       0.000
  Depth                                                                                                                                          
   Deep seated                                          23 244 (64.9%)         19 490 (64.3%)                 6592 (66.2%)                       
   Superficial                                          7007 (19.6%)           6043 (20.5%)                   1724 (17.3%)                       
   Not reported                                         5533 (15.5%)           4494 (15.2%)                   1638 (16.5%)                       0.000
  Category                                                                                                                                       
   Sarcoma                                              29 500 (82.4%)         24 148 (81.9%)                 8346 (83.8%)                       
   Intermediate malignancy                              6284 (17.6%)           5349 (18.1%)                   1608(16.2%)                        0.000
  Histological subtype (11 most frequent)                                                                                                        
   Leiomyosarcoma                                       4182 (11.7%)           3396 (11.5%)                   837 (8.4%)                         
   UPS                                                  3867 (10.8%)           3495 (11.8%)                   1253 (12.6%)                       
   GIST                                                 2690 (7.3%)            2112 (7.2%)                    637 (6.4%)                         
   DDLPS                                                2277(6.4%)             2114 (7.2%)                    777 (7.8%)                         
   WDLPS                                                2110 (5.9%)            1714 (5.8%)                    842 (8.5%)                         
   Desmoid                                              1814 (5.1%)            1603 (5.4%)                    205 (2.1%)                         
   Myxofibrosarcoma                                     1170 (3.3%)            995 (3.4%)                     362 (3.6%)                         
   Chondrosarcoma                                       1136 (3.2%)            901 (3.1%)                     454 (4.6%)                         
   Ewing                                                1136 (3.2%)            946 (3.2%)                     360 (3.6%)                         
   Angiosarcoma                                         1117 (3.1%)            985 (3.3%)                     278 (2.8%)                         
   Synovial                                             966 (2.7%)             741 (2.5%)                     192 (2.9%)                         0.000
  Others (144 histotypes, *N* range 1--904)             13 319 (37.4%)         10 495 (35.6%)                 3757 (37.7%)                       
  Grade                                                                                                                                          
   1                                                    3965 (11.1%)           3058 (10.4%)                   1370 (13.8%)                       0.000
   2                                                    6165 (17.2%)           5053 (17.1%)                   1910 (19.2%)                       0.000
   3                                                    7616 (21.3%)           6509 (22.1%)                   2559 (25.7%)                       0.000
   Unknown                                              10 163 (28.4%)         8576 (29.1%)                   2309 (23.2%)                       0.000
   Non-applicable                                       7875 (22.2%)           6301 (21.4%)                   1806 (18.1%)                       0.000
  Site of the primary tumor                                                                                                                      
   Lower limb                                           9342 (26.1%)           7805 (26.5%)                   3693 (37.1%)                       0.000
   Thigh                                                4636 (13%)             3872 (13.1%)                   1935 (19.4%)                       0.000
   Upper limb                                           3487 (9.7%)            2861 (9.7%)                    977 (9.8%)                         0.631
   Trunk wall                                           5506 (15.4%)           4783 (16.2%)                   1535 (15.4%)                       0.008
   Retroperitoneum                                      2945 (8.2%)            2278 (7.7%)                    915 (9.2%)                         0.000
   Gastrointestinal                                     2890 (8.1%)            2417 (8.2%)                    679 (6.8%)                         0.000
   Uterus                                               1733 (4.8%)            1357 (4.6%)                    224 (2.3%)                         0.000
   Head and neck                                        2162 (6.0%)            1774 (6.0%)                    341 (3.4%)                         0.000
   Other                                                7719 (21.6%)           6622 (21.1%)                   1610 (16.1%)                       0.000
  Metastases at diagnosis                                                                                                                        
   No                                                   27 952 (78.1%)         23 006 (78.0%)                 8566 (86.1%)                       
   Yes                                                  4180 (11.6%)           3603 (12.2%)                   701 (7.1%)                         
   Unknown                                              3652 (10.2%)           2888 (9.8%)                    687 (6.9%)                         0.000
  N pts operated                                        31 863 (89.0%)         25 851 (87.6%)                 9954 (100%)                        
  Patients presented to NETSARC MDTB before treatment   NA                     14 509 (49.2%)                 6372 (64.0%)                       0.000

*P*-value comparing patients operated outside versus inside NETSARC centers.

DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; NA, Not applicable; UPS, undifferentiated pleomorphic sarcoma; WDLPS, well differentiated liposarcoma.

Characteristics of patients operated in NETSARC centers
-------------------------------------------------------

Among the 29 497 incident patients, 9954 (33.7%) had a first surgery in a NETSARC center, 15 896 (54.8%) had been operated outside of a NETSARC center, 3647 (12.4%) had not been resected at last follow-up. Among those operated, the proportion operated in a NETSARC center increased from 30.4% to 42.9% from 2010 to 2017 (*P* \< 0.001). 14 509 (49.2%) patients of the incident population were presented to a NETSARC MDTB before first treatment (Table [1](#mdz124-T1){ref-type="table"}), the proportion increased from 33.3% to 56.2% between 2010 and 2017.

We analyzed the characteristics of patients operated in NETSARC in the incident group (*N* = 29 497, since January 2010) (Table [1](#mdz124-T1){ref-type="table"}). Overall, the characteristics of patients operated in a NETSARC center were less favorable, with a higher proportion of patients with large tumors (*P* \< 0.001), grade 3, retroperitoneal, UPS histology and a lower proportion of patients with tumors of intermediate malignancy (all *P* \< 0.001). A lower proportion of sarcoma from uterus, head and neck, or internal trunk, GIST, desmoid tumors, and tumors of intermediate malignancy was observed in patients operated in NETSARC centers (Table [1](#mdz124-T1){ref-type="table"}).

More patients operated in NETSARC had been presented to a NETSARC MDTB (64.0% versus 41.7%, *P* \< 0.001) before surgery, as expected. Biopsy (core or incisional) before surgery were carried out in 8585 of 15 897 (54.0%) patients operated outside NETSARC versus 8096 of 9954 (81.3%) of patients operated in NETSARC (*P* \< 0.001). Adequate imaging before surgery had been carried out in 9378 (59.0%) versus 8239 (82.8%) of patients operated outside versus within NETSARC (*P* \< 0.001).

Table [2](#mdz124-T2){ref-type="table"} describes the predisposing conditions reported for the 35 784 patients, the number of different histological subtypes associated with these conditions. Previous cancer, previous RT, a diagnosis of NF1, and immune-depression were the most frequent predisposing condition. All others were observed in ≤0.1% of patients. Preexisting conditions were generally associated with specific predominant histological subtypes, consistently with the literature (Table [2](#mdz124-T2){ref-type="table"}) \[[@mdz124-B1]\].

###### 

History of previous cancer or cancer predisposition

                                             *N* (%)         Number of different histotypes (total *N* = 155)   Predominant histotype   *N* (%)
  ------------------------------------------ --------------- -------------------------------------------------- ----------------------- -------------
  History                                                                                                                               
  None                                       20 540 (57.4)   153 (98.7)                                         LMS                     2327 (11.3)
  Unknown                                    7098 (19.8)     137 (88.4)                                         LMS                     868 (12.2)
  Previous cancer                            4577 (12.2)     119 (76.8)                                         UPS                     690 (15.1)
  In irradiated field                        1125 (3.1)      89 (57)                                            Angiosarcoma            376 (30.7)
  NF1                                        288 (0.8)       25 (16)                                            MPNST                   186 (64.6)
                                                                                                                GIST                    50 (17.7)
  Immunodepression                           139 (0.4)       37(23.8)                                           Kaposi                  64 (46.0)
  Gardner                                    51 (0.1)        1 (0.6)                                            Desmoids                51 (100)
  Multiple exostoses                         43 (0.1)        3 (0.6)                                            Chondrosarcoma          38 (88.4)
  Ollier                                     39 (0.1)        8 (5.1)                                            Chondrosarcoma          33 (81.2)
  Li--Fraumeni                               37 (0.1)        23 (14.8)                                          LMS                     8 (21.6)
  Paget disease of bone                      20 (0.1)        13 (8.3)                                           Osteosarcoma            5 (25)
  Retinoblastoma                             16 (0.04)       9 (5.8)                                            LMS                     6 (37)
  Rothmund--Thomson                          2 (0.005)       1                                                  Osteosarcoma            
  Maffucci syndrome                          2 (0.005)       1                                                  Chondrosarcoma          
  NF2                                        1 (0.003)       1                                                  GIST                    
  Werner syndrome                            1 (0.003        1                                                  LPS                     
  Stratiakis-Carney                          1 (0.003)       1                                                  GIST                    
  Other[^a^](#tblfn3){ref-type="table-fn"}   2773 (7.7)      124 (80.0)                                         LMS                     311 (11.2)

No details are provided in the database.

GIST, gastrointestinal stromal tumor; LMS, leiomyosarcoma; NF1, neurofibromatosis type 1; UPS, undifferentiated pleomorphic sarcoma.

A previous diagnosis of cancer (12.7% versus 11.58, *P* = 0.03), sarcoma in an irradiated field (4.0% versus 3.0%, *P* \< 0.001), history of Ollier's disease (0.2% versus 0.1%, *P* = 0.003), and multiple exostoses (0.2% versus \<0.1%, *P* \< 0.001) were more frequently reported in patients operated in NETSARC centers. Conversely, a history of Gardner's disease (\<0.1% versus 0.1%, *P* = 0.02), retinoblastoma (\<0.1% versus 0.1%, *P* = 0.02), and immunodepression (0.2% versus 0.4%, *P* = 0.04) were less frequently reported in patients operated in NETSARC centers reflecting probably referral patterns from organ specialists. A history of NF1 and of a Li--Fraumeni syndrome was observed at similar levels in the two groups of patients.

Quality of surgery
------------------

The quality of the surgery of operated patients was then compared between the two groups including only the 25 851 \[patients who had been operated of their primary tumor (87.6% of the incident patient population\]. Table [3](#mdz124-T3){ref-type="table"} presents the rate of R0, R1, and R2 resection in NETSARC and non-NETSARC centers, at initial surgery, and after final surgery: the R0 rate in NETSARC centers was over twofold that of non-NETSARC centers, while the proportion of R2 and R unknown surgery was over twofold higher in non-NETSARC centers (Table [3](#mdz124-T3){ref-type="table"}, *P* \< 0.001). The rate of reoperation was also over twofold superior in non-NETSARC centers (Table [3](#mdz124-T3){ref-type="table"}). Figure [1](#mdz124-F1){ref-type="fig"}A--C presents LRFS, EFS, and OS according to the R status in all 25 851 operated incident patients. The absence of a documented R was associated with a higher risk of relapse and death: the R2 and R unknown groups had a similar OS indicating that the lack of information is by itself a negative predictive marker (Figure [1](#mdz124-F1){ref-type="fig"}).

![Relapse and survival of the incident population of 29 497 patients. (A, B, C) Local relapse free survival (LRFS), event-free survival (EFS) and overall survival (OS) of patients with a final R0, R1, R2 and R unknown resection. (D, E, F) LRFS, EFS and OS of patients operated with a NETSARC center or outside a NETSARC center.](mdz124f1){#mdz124-F1}

###### 

Quality of resection in patients operated within or outside NetSARC

                 First surgery outside NETSARC or no data (*N* = 15 897), *n* (%)   First surgery in NetSARC (*N* = 9954), *n* (%)       *P*
  ------------- ------------------------------------------------------------------ ------------------------------------------------ -------------
  Initial                                                                                                                           
   R0                                      3113 (19.6)                                               5280 (53.0)                    
   R1                                      3208 (20.2)                                               2388 (24.0)                    
   R2                                       1659 (8.5)                                                417 (4.2)                     
   Unknown                                 7917 (50.0)                                               1869 (18.8)                     **\<0.000**
  Reoperation                              2498 (15.7)                                                616 (6.2)                      **\<0.000**
  Final                                                                                                                             
   R0                                      4693 (29.5)                                               5643 (56.7)                    
   R1                                      2492 (15.7)                                               2170 (21.8)                    
   R2                                       981 (6.2)                                                 302 (3.0)                     
   Unknown                                 7731 (48.6)                                               1839 (18.5)                     **\<0.000**

The bold characters are used when the *P* value is significant.

Survival
--------

Prognostic factors for relapse and death were then evaluated in the incident population of 25 851 operated patients. Table [4](#mdz124-T4){ref-type="table"} presents the prognostic factors for LRFS, EFS, and OS, with a median follow-up of 17 months. Grade, tumor site, histotype, tumor size, and age were correlated to OS, EFS, and local relapse (Table [4](#mdz124-T4){ref-type="table"}). Previous cancer, previous RT, and NF1 diagnosis also correlated negatively to event-free and OS. No other genetic predisposition influenced LRFS, EFS, or OS in this series. Presentation of patients to an MDTB before initial treatment, and surgery in a NETSARC center correlated to a better LRFS, EFS, while OS was worse in this subgroup (not shown). Importantly, initial surgery in a NETSARC center was associated with a significantly improved EFS and OS (Figure [1](#mdz124-F1){ref-type="fig"}D--F). This was observed regardless of the number of patients operated in individual NETSARC center (not shown). The OS of patients presented to a NETSARC MDTB and operated outside of NETSARC center was particularly poor ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

###### 

Prognostic factors for local relapse free (LRFS), event-free (EFS) and overall survival (OS) in the operated incident patient population (*N* = 25 851)

                                  LRFS             EFS             OS                                    
  -------------------------- --------------- --------------- --------------- --------------- ----------- -----------
  Parameter                                                                                              
   Male gender                    1.015           0.649       **1**.**098**   **0**.**045**   **1.213**   **0.000**
   Age                          **1.010**       **0.000**     **1**.**008**   **0**.**000**   **1.015**   **0.000**
   Bone                           0.999           0.986           0.881           0.068       **1.435**   **0.000**
   Visceral                       1.097           0.058           1.050           0.588       **1.878**   **0.002**
   Deep seated                    0.943           0.097           1.050           0.431       **1.488**   **0.000**
  Tumor size                    **1.002**       **0.000**     **1**.**002**   **0**.**000**   **1.003**   **0.000**
  Histological subtype                                                                                   
   Leiomyosarcoma               **0.690**       **0.000**     **1**.**129**   **0**.**082**   **0.700**   **0.000**
   UPS                            1.075           0.145           0.940           0.397       **1.201**   **0.003**
   GIST                         **0.267**       **0.000**     **0**.**254**   **0**.**000**   **0.158**   **0.000**
   DDLPS                        **1.271**       **0.000**     **0**.**789**   **0**.**019**   **0.830**   **0.016**
   WDLPS                        **0.633**       **0.000**     **0**.**516**   **0**.**000**   **0.197**   **0.000**
   Desmoid                      **1.490**       **0.000**         1.079           0.630       **0.227**   **0.000**
   Intermediate malignancy        0.965           0.462       **0**.**520**   **0**.**000**   **0.122**   **0.000**
  Grade                                                                                                  
   1                          **0**.**716**   **0**.**000**   **0**.**635**   **0**.**000**   **0.347**   **0.000**
   2                              1.074           0.100           1.013           0.854         1.020       0.754
   3                            **1.335**       **0.000**     **1**.**540**   **0**.**000**   **2.091**   **0.000**
  Site                                                                                                   
   Lower limb                   **1.015**       **0.766**     **0**.**843**   **0**.**035**   **0.760**   **0.000**
   Upper limb                   **1.376**       **0.000**         0.892           0.252       **0.692**   **0.000**
   Trunk wall                   **1.369**       **0.000**         1.025           0.777         1.045       0.541
   Uterus                       **1.245**      **0, 005**         1.230           0.071       **1.672**   **0.000**
   Retroperitoneal sarcoma      **1.773**       **0.000**       **1.364**       **0.004**     **1.262**   **0.006**
   Other internal trunk         **1.374**       **0.000**         1.068           0.511       **1.532**   **0.000**
   HN                           **1.645**       **0.000**         1.122           0.336         1.009       0.930
  Metastasis at diagnosis         1.004           0.946         **3.082**       **0.000**     **3.834**   **0.000**
  Preexisting conditions                                                                                 
   Previous cancer              **1.129**       **0.013**         1.016           0.815       **1.193**   **0.007**
   Previous RT                  **1.557**       **0.000**         1.020           0.334       **1.763**   **0.000**
   NF1                          **1.393**       **0.027**       **1.524**       **0.035**     **2.072**   **0.000**
   P53                            0.652           0.340           1.868           0.168         0.292       0.219
   Immunodepression               0.978           0.940           1.149           0.716         0.629       0.300
   Rb                             1.761           0.258           1.005           0.995         0.919       0.932
   Gardner                        1.691           0.165           1.894           0.278         0.404       0.365
   Ollier                         0.785           0.588           2.222           0.262         0.739       0.675
   Multiple exostose              1.004           0.946           0.632           0.647         0.000       0.339

The bold characters are used when the *P* value is significant.

DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; HR, hazard ratio; NF1, neurofibromatosis type 1; UPS, undifferentiated pleomorphic sarcoma; WDLPS, well differentiated liposarcoma.

In multivariate analysis, LRFS, EFS, and OS were influenced by patient related factors (gender, age), tumor presentation (site, size, location, metastases at diagnosis), histotypes, and grade. In addition, previous RT negatively correlated to LRFS. Importantly, NF1 condition was the strongest negative prognostic factor for LRFS, EFS, and OS (Table [5](#mdz124-T5){ref-type="table"}). Surgery in a NETSARC center was found consistently associated with a reduction in the risk of local relapse, progression, and death, with hazard ratio of 0.64, 0.83, and 0.68 for LRFS, EFS, and OS (Table [5](#mdz124-T5){ref-type="table"}). The favorable prognostic value of surgery in a NETSARC center was retained in addition to the presentation to a NETSARC MDTB. The later also remain an independent prognostic factor associated with a reduction in the risk of local relapse and EFS, but not OS (Table [5](#mdz124-T5){ref-type="table"}).

###### 

Multivariate analysis of prognostic factors for relapse and survival in the incident population of operated patients

                                   Hazard ratio        (95% CI)        *P*-value
  ------------------------------- -------------- -------------------- -----------
  Local relapse free survival                                         
   NF1                                1.748         (1.297--2.354)       0.000
   Desmoid tumor                      1.670         (1.420--1.965)       0.000
   Previous RT                        1.532         (1.335--1.756)       0.000
   Retroperitoneal sarcoma            1.362         (1.213--1.529)       0.000
   Bone                               1.290         (1.167--1.425)       0.000
   Grade 3                            1.181         (1.098--1.269)       0.000
   DDLPS                              1.157         (1.029--1.302)       0.016
   Head and neck sarcoma              1.124         (0.988--1.279)       0.075
   UPS                                1.100         (0.995--1.215)       0.063
   Age at diagnosis                   1.008         (1.006--1.010)       0.000
   Deep                               0.930         (0.866--0.998)       0.041
   Lower limb                         0.872         (0.808--0.941)       0.001
   Intermediate malignancy            0.820         (0.734--0.915)       0.000
   Grade 1                            0.689         (0.615--0.772)       0.000
   NETSARC MDT before treatment       0.670         (0.623--0.720)       0.000
  Surgery in a NETSARC center       **0.654**     **(0.610--0.702**)     0.000
   LMS                                0.650         (0.585--0.723)       0.000
   GIST                               0.279         (0.229--0.341)       0.000
  Disease-free survival                                               
   Metastases at diagnosis            1.766         (1.646--1.896)       0.000
   NF1                                1.537         (1.222--1.933)       0.000
   Size ≥100 mm                       1.431         (1.328--1.541)       0.000
   Grade 3                            1.392         (1.319--1.467)       0.000
   Uterine sarcoma                    1.300         (1.162--1.453)       0.000
   Retroperitoneal sarcoma            1.260         (1.136--1.398)       0.000
   Desmoid tumor                      1.219         (1.048--1.418)       0.010
   Previous RT                        1.195         (1.064--1.341)       0.003
   Bone                               1.169         (1.085--1.259)       0.000
   UPS                                1.095         (1.019--1.178)       0.015
   Gender                             1.094         (1.042--1.149)       0.000
   Visceral                           1.083         (0.988--1.188)       0.093
   Age at diagnosis                   1.007         (1.005--1.009)       0.000
   Trunk wall                         0.893         (0.821--0.972)       0.009
   Upper limb                         0.890         (0.807--0.981)       0.019
   Lower limb                         0.874         (0.808--0.945)       0.001
   Head and neck sarcoma              0.873         (0.773--0.986)       0.028
   DDLPS                              0.857         (0.779--0.944)       0.002
  Surgery in a NETSARC center       **0.843**     **(0.799--0.889**)     0.000
   NETSARC MDT before treatment       0.800         (0.758--0.843)       0.000
   WDLPS                              0.653         (0.561--0.761)       0.000
   Intermediate malignancy            0.649         (0.590--0.715)       0.000
   Grade 1                            0.590         (0.534--0.652)       0.000
   GIST                               0.324         (0.281--0.373)       0.000
  Overall survival                                                    
   Metastases at diagnosis            3.153         (2.852--3.483)       0.000
   NF1                                2.467         (1.761--3.456)       0.000
   Size ≥100 mm                       1.981         (1.760--2.227)       0.000
   NETSARC MDT before treatment       1.563         (1.423--1.718)       0.000
   Grade 3                            1.511         (1.381--1.654)       0.000
   Previous RT                        1.335         (1.113--1.602)       0.002
   Visceral                           1.333         (1.156--1.539)       0.000
   Bone                               1.278         (1.112--1.468)       0.001
   Uterine sarcoma                    1.246         (1.034--1.501)       0.021
   Deep                               1.229         (1.108--1.363)       0.000
   Gender                             1.189         (1.086--1.301)       0.000
   UPS                                1.133         (1.002--1.282)       0.048
   Age at diagnosis                   1.017         (1.015--1.019)       0.000
   Trunk wall                         0.832         (0.728--0.951)       0.007
   DDLPS                              0.782         (0.667--0.916)       0.003
  Surgery in a NETSARC center       **0.681**     **(0.618--0.749**)   **0.000**
   Lower limb                         0.663         (0.585--0.752)       0.000
   Upper limb                         0.621         (0.519--0.742)       0.000
   LMS                                0.615         (0.537--0.704)       0.000
   Grade 1                            0.431         (0.342--0.544)       0.000
   WDLPS                              0.385         (0.245--0.605)       0.000
   GIST                               0.154         (0.117--0.203)       0.000
   Intermediate malignancy            0.154         (0.112--0.212)       0.000

The bold characters are used when the *P* value is significant.

DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; HR, hazard ratio; LMS, leiomyosarcoma; NF1, neurofibromatosis type 1; UPS, undifferentiated pleomorphic sarcoma; WDLPS, well differentiated liposarcoma.

When the analysis was conducted in the same incident population of sarcoma, excluding patients with metastatic disease at diagnosis (*N* = 23 327), surgery in a NETSARC center remained an independent prognostic factor for LRFS, EFS, and OS (not shown). Similarly, this analysis was conducted in the entire population of 35 784 patients, pooling incident patients (*N* = 29497), and patients diagnosed before 1 January 2010 (*N* = 6287). The latter group is of course biased with an over representation of longer survivors and of relapsing patients given the mode of entry of a presentation to an MDTB. Surgery in a NETSARC center was retained as independent favorable prognostic factors for LRFS, EFS, and OS in this exhaustive series (not shown).

Discussion
==========

In the present work, we investigated the impact of surgery in a reference center for sarcoma on relapse and survival in a nationwide series of 35 784 sarcoma patients seen in NETSARC MDTB since 2010. We focused on the population of incident patients diagnosed from 1 January 2010. We also analyzed the incidence and prognostic impact of preexisting conditions.

Clinical practice guidelines recommend a multidisciplinary management by reference centers for rare cancers, in particular for sarcoma \[[@mdz124-B5]\]. Management in large volume centers and in network of reference centers improves adhesion to clinical practice guidelines \[[@mdz124-B12]\].

The NETSARC network aims at improving the management of sarcoma patients and their outcome nationwide. NETSARC prospectively collected all sarcoma cases reviewed in one of the 26 MDTB of the network since 1 January 2010. Centralized expert pathology review by the RREPS network is mandatory nationwide since 1 January 2010, ensuring that the diagnosis of sarcoma reported in this database is accurate. It took 3 years for NETSARC to accrue each year the number of expected incident patients. Since 2013, the number of new cases of sarcomas included in the database reached the expected incidence of these diseases in this country of 67 million inhabitants, with a 6.2/100 000/year incidence \[[@mdz124-B2]\]. These numbers strongly suggest that this database gathers a close to exhaustive nationwide cohort of sarcoma patients.

In this work, we focused the survival analysis on the 29 497 incident patients with sarcoma with an initial diagnosis from 1 January 2010 to 1 May 2018. The analysis of this prospective nationwide cohort of patients indicates that the survival of sarcoma patients is improved when they are operated in a reference center. When surgery is not carried out in a reference center (*N* = 15 897), the rate of R0 resections is 50% lower to that of patients operated in a NETSARC center, while conversely the rate of R2 resection is more than doubled. Reoperations are carried out 2.5-fold more often in patients firstly not operated in a NETSARC center. Finally, the quality of the final surgical intervention of patients operated upfront outside NETSARC center, as evaluated by the rate of R0, R1, R2, and unknown resection, was significantly inferior even after a secondary surgery: with a lower rate of R0 resection and a higher rate of R2 resection. Importantly, this documentation of the quality of surgery was missing in a significantly higher proportion for surgeries carried out outside a NETSARC center versus NETSARC center. The lack of documentation of the R status is by itself a negative prognostic factor. When the primary surgery was done outside a NETSARC center, a secondary surgery in a NETSARC center did not allow to compensate the initial low rate of R0 surgery: the rate of inadequate surgery (R2, R unknown) surgery as final surgery remain significantly increased in the population of patients which was not initially operated in a NETSARC center.

As expected, reoperations were more frequent in patients operated outside NETSARC. We previously reported that this was an important component of the increased cost of the patient pathways for patients operated outside NETSARC \[[@mdz124-B23], [@mdz124-B24]\]. This study estimated a €4000 net increase of the cost of the overall procedure per patient managed outside guidelines, and it is noteworthy that over 50% of the 29 497 patients had either no previous biopsy, no adequate imaging, or were operated outside NETSARC. Not only these patients had a higher relapse rate and worse survival, but the excess cost of their suboptimal treatment may be estimated to 60 million euros over the study period \[[@mdz124-B25], [@mdz124-B26]\].

Patients operated in a NETSARC center had significantly worse prognostic characteristics as compared with those operated outside NETSARC, with larger tumors of higher grade and unfavorable locations (retroperitoneal) and histological subtypes; however, the differences in the two groups probably also reflected referral patterns of organ specialists, with a lower proportion of sarcoma from uterus, head and neck, or GIST in NETSARC centers, as well as less immunosuppressed patients and Gardner syndromes. These differences also reflected practices: for desmoid tumors, where the strategy of watchful waiting has been proposed in reference centers since a decade \[[@mdz124-B27], [@mdz124-B28]\], the proportion of operated patients was very low in NETSARC centers. Surgery in a NETSARC center is an independent prognostic factor for LRFS, EFS, and OS. The reduction of the risk of relapse and death is close to 35% indicating that centralization of surgery is probably the most efficient, and actually cost saving strategy to improve survival and reduce the risk of relapse and death of sarcoma patients in localized phase. Indeed, no other treatment procedure or medication is reported to enable such an increase survival of sarcoma patients to this extent, in view of the current scientific literature.

The improvement in survival observed when surgery is carried out in a NETSARC center comes in addition to the presentation to a NETSARC MDTB in the multivariate model. We had previously reported in the series of the first 12 528 patients that the presentation of the patient to an MDTB before any treatment procedure is associated with a better compliance to the clinical practice guidelines, a better quality of surgery, a better relapse free survival \[[@mdz124-B12]\]. This later parameter is indeed associated with a better LRFS and EFS as previously described \[[@mdz124-B12]\], but correlates to a worse OS, both in univariate and multivariate analysis. This is an intriguing observation for which we could formulate two non-mutually exclusive hypotheses: (i) presentation to a NETSARC MDTB is correlated to additional negative prognostic parameters not yet characterized and then not integrated in the multivariate model; (ii) this patient population has complex clinical characteristics requiring experienced surgical teams. [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} (available at *Annals of Oncology* online) shows that patient population presented to a NETSARC MDTB but not operated in a NETSARC center is at higher risk of relapse, but represents also the population at highest risk of death, even higher than the patient population which was not presented to an MDTB and not operated in NETSARC.

Thirty-six percent of patients operated in NETSARC centers had not been presented before surgery in the MDTB. While this was observed more often in small \< 3 cm tumors and visceral sites (not shown), these figures must be improved. A research program is ongoing to understand these situations.

These observations indicate that presentation to a specialized MDTB cannot be the single recommended measure, and does not constitute a sufficient organizational process for sarcoma patients, if the subsequent surgery was not carried out in a NETSARC reference center. Overall, this analysis shows that two core components, presentation to a specialized sarcoma MDTB and surgical management, must be conducted in a NETSARC center to achieve optimal tumor control and survival in sarcoma patients in this country. Presentation to a specialized MDTB, while surgery is not carried out in a reference center is actually associated with the worst survival in this series. Guidance for the treatment from reference centers to non-expert centers is not sufficient and execution of the treatment by reference centers is needed to improve patient survival. Importantly, consistent results were recently reported in other countries with different health care systems \[[@mdz124-B14], [@mdz124-B29]\]: management in reference centers in The Netherlands and in Spain is associated with an improved outcome. This shows that the organized management in reference center for sarcoma may be able to improve survival of sarcoma patients regardless of the health care system.

Several preexisting conditions strongly influenced the risk of relapse and survival in this nationwide study. Previous cancer, previous RT, and most importantly a history of NF1 are correlated with an increased risk of local relapse, progression, and worse survival in univariate analysis. Importantly, the two latter parameters were retained in multivariate analysis, as independent prognostic factors for local relapse (for previous RT) and for all three parameters (NF1). Actually NF1 was identified as one of the strongest adverse parameter for LRFS, EFS, and OS. This observation had not been previously reported in such a large national series and point out to explore innovative strategies, possibly specifically targeting the activated biological pathway in addition to classical treatments.

This series has several limitations: the limited follow-up, a lack of exhaustivity in the first years of network operations, and the proportion of patients with unspecified information. It is planned to expand progressively the numbers of mandatory field, which must be completed to upload the clinical case to improve the latter issue. The description of pre- and postoperative treatment is also very limited. It is important to mention that this study is not a clinical trial. A regular and systematic update of the follow-up of these patients will be important to explore patient outcome for the longer term. Nevertheless, this series is to our knowledge among the largest prospective series of sarcoma patients collected at a national level. Importantly, it is close to exhaustivity since 2013, based on the expected incidences of these tumors. These results provide a tangible confirmation of the statements proposed in clinical practice guidelines for sarcomas: treatment carried out from the initial surgical steps in reference centers offers a greater chance of disease free and OS in sarcoma. These results show that early referral, management, and treatment in reference center improve the quality of initial surgery, reduce the risk of reoperation, and improve survival to a magnitude never achieved with any new therapeutic intervention. This management may also occur at a lower overall treatment cost \[[@mdz124-B23], [@mdz124-B24]\]. These observations are likely to be relevant to other rare cancers, which altogether represent 20% of all cancers and often share the same management issues \[[@mdz124-B30], [@mdz124-B31]\]. The worse survival reported in many series is better understood based on the present results.

In conclusion, these results show that the management of patients with sarcomas must be carried out by a multidisciplinary team with experience in the management of sarcoma, from the diagnostic phase, before any treatment initiation, and for at least the first surgical treatment. When the management is not done in reference centers, clinical practice guidelines, are less frequently applied, with an increased risk of relapse, reoperation, and death. This study also identifies NF1 as a major adverse prognostic factor increasing the risk of relapse and death to a larger magnitude than any other parameter in non-metastatic patients.
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